VBIO NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Valion Bio Inc · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 0.31 USD
4.4% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -63.3% below the Trend Line and sits at 1.1% of its 52-week range. The latest completed week returned 4.4%, after a -37.9% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 50/100. Near-term considerations: earnings are due in 11d.

Setup score 15 out of 100
Latest Close 0.31 USD 31 Jul 2026
1W Return 4.4% latest completed week
4W Return -37.9% short-term follow-through
12W Return -67.7% quarterly tape
Trend Breadth 0.0% 0 of 52 weeks active
Volume Ratio 1.6x vs 13-week average
What is working
  • Volume is elevated versus the 13-week average, confirming attention.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 4.4% Latest completed week; four-week move -37.9%. Indicator stack 0/0 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 34.29% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 50/100 26 relevant articles in the latest sentiment read. Event risk 11d Next report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -63.3% below the Trend Line and sits at 1.1% of its 52-week range. The latest completed week returned 4.4%, after a -37.9% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 1.6x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest -0.0012-week average 0.04

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure7/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure-0.00Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -37.9% over four weeks, -67.7% over 12 weeks, and -90.4% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W4.4%
4W-37.9%
12W-67.7%
26W-73.9%
52W-90.4%
Active trend streak0 weeks
Active weeks in one year0
Trend breadth0.0%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.50Latest activity-pressure read.
Pressure change-782.0%Four-week change in activity pressure.
Leadership-82.44Latest relative-leadership reading.
RS change-6.9%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 67% Model confidence 64%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength77/100Blend of value, momentum, and quality. Underlying universe rank 24; rank 1 is best.
Value63/100Relative valuation strength. Underlying universe rank 38; rank 1 is best.
Quality62/100Profitability and accounting quality. Underlying universe rank 39; rank 1 is best.
Momentum64/100Medium-term price momentum. Underlying universe rank 37; rank 1 is best.
Growth64/100Revenue and earnings growth. Underlying universe rank 37; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-264.5%
Operating profit retained from revenue.
Free-cash-flow margin
-275.3%
Free cash flow generated from revenue.
Return on invested capital
-15.0%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
3/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-
Net share repurchases relative to market value.
Shareholder yield
-
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.3x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment50/100

Weighted news tone is neutral across 26 relevant articles.

2 positive · 23 neutral · 1 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings11dNext report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-94.5%Distance below the 52-week high.
13-week volatility12.9%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher11 of 2615 weeks finished lower.
Best week+35.4%Week of 17 Apr.
Worst week-41.2%Week of 24 Jul.
Latest week+4.4%Week of 31 Jul.

Shape of recent returns

Strong gains8
Modest gains3
Flat weeks0
Modest losses4
Sharp losses11
Recent vol12.9%13-week weekly-return volatility.
Base vol12.2%52-week weekly-return volatility.
Up/down split19/33Count of positive and negative weeks in the 52-week window.
Average skew7.6% / -10.0%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape15/100

Trend, activity pressure, participation, and risk combine to a 15/100 tape read.

 Indicator analysis30/100

Latest 12-week confirmation: trend 0/12, activity pressure 7/12, relative leadership 0/12.

Activity pressure -0.00; No reversal markers Next-Week ExpectancyNegative 34.29%

Next-week expectancy is negative with a 34.29% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors66/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 50 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment50/100

Weighted news tone is neutral across 26 relevant articles.

Valion Bio Inc (NASDAQ: VBIO) Share Price, VBIO Stock News, VBIO Share Price & Updates Insiders50/100

No recent insider transaction evidence is stored.

 Earnings11d

Next report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20260.31 USD4.4%0.84 USD10.12 USD-0.50-82.444.1MOff
24 Jul 20260.30 USD-41.2%0.88 USD10.90 USD-0.40-83.7411.3MOff
17 Jul 20260.51 USD-0.8%0.92 USD11.44 USD-0.31-74.102.2MOff
10 Jul 20260.51 USD2.0%0.97 USD11.93 USD-0.30-76.05310.1KOff
3 Jul 20260.50 USD-10.1%1.02 USD12.61 USD-0.06-77.10406.4KOff
26 Jun 20260.56 USD6.8%1.07 USD13.80 USD0.16-75.312.1MOff
19 Jun 20260.52 USD-8.2%1.11 USD14.95 USD0.30-78.73588.2KOff
12 Jun 20260.57 USD-25.5%1.15 USD16.06 USD0.53-77.087.5MOff
5 Jun 20260.76 USD-0.8%1.19 USD17.13 USD0.62-69.58410.2KOff
29 May 20260.77 USD-10.1%1.24 USD18.15 USD0.76-71.71254.9KOff
22 May 20260.85 USD-3.1%1.30 USD19.34 USD0.83-68.74440.1KOff
15 May 20260.88 USD-8.3%1.37 USD20.53 USD0.96-68.441.2MOff
8 May 20260.96 USD4.3%1.44 USD21.93 USD1.02-66.822.7MOff
1 May 20260.92 USD-30.8%1.50 USD23.86 USD0.95-67.491.0MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.